Upload
others
View
0
Download
0
Embed Size (px)
Citation preview
Driving Efficiency in Pre-Clinical Development with Automated Mass-Spectrometry Analysis and Characterization of Novel Biologics
Hirsh NandaJanssen Pharmaceuticals, Spring House PACell & Developability Sciences, BioTD
September 12, 2018
CASSS MS 2018
Pharmaceutical Development & Manufacturing Sciences 2
Target Research “Target
validation”
Hit and Lead Generation“Candidate
source”
Lead Optimization“Candidate
Engineering”
Cell & Developability
Sciences
GMP Batch Development
NME IND
Steps in Large Molecule Early Development
DiscoveryDevelopment
102-103 10-20 1-4Num
ber
of
Can
dida
tes:
Drive candidate selection and development of the manufacturing cell line
Developability | Early Formulation | Cell Line Development
C e l l & D e v e l o p a b i l i t y S c i e n c e s
Pharmaceutical Development & Manufacturing Sciences
DEVELOPABILITY process
In SilicopItheo
PTM risks/motifsSAP
3
* If appropriateSIA: Stability Indicating AssaysIMW: Intact Mass Spectrometry
ReleaseBuffer Screen
cIEFHIC
IMWDLS
CaliperSEC
CEX*DSC
Fab arm exch*
Free Thiol*
ConcentrationA280/A350 conc@ 0, 1 & 4 weeks
Serum CompSEC
pH3.5Aggregation
FeOxidation
H2O2Oxidation
SIA
DLScIEF
SECIMW
Caliper
PTM Risk
40˚Caggregation
pH8.5deamidation
MS Methods
Activity Assays
81 Assays per Candidate
Pharmaceutical Development & Manufacturing Sciences
Cell Line Development and Clone SelectionExpression vector (DNA for mAb)
Host cells
Expand top clone(s)2nd screen - Clonality
Productivity
Expressing Stability
Cell Culture Performance
Product Quality
1st screen – Rare expressers
Productivity
Manufacturing Cell Line
5
In Depth Characterization and Key Analytical Readouts
uSP Screen Developability Cell Line Selection
Sequence Variance
, Signal Peptide
Off-Platform Programs Present New Challenges to Molecule Characterization
Alternative Scaffolds
ADC
Multi-Specifics
Vaccines
>50% of the Early Pipeline are not mAb
- Large molecule therapeutics susceptible to numerous post-translational modifications and other variants- Off-platform biologics have only added to this complexity
Complexity of Biologics
Challenges : Know More Sooner
- Characterization and PTM analysis of multiple different candidate molecules within pre-clinical development.
- “Speed to IND”
Fast Turn-around Time
Mass spectrometry data provides information on many important molecule attributes but often requires multiple software packages and extensive manual interpretation.
Complexity of MS Data
Bottom Up and Intact Mass Approach for Molecule Characterization
8
Intact Mass Analysis PipelinePeptide Mapping Analysis
Peptide Mapping Intact Mass & Subunit
Bottom Up and Intact Mass Approach for Molecule Characterization
9
Intact Mass Analysis PipelinePeptide Mapping Analysis
Peptide Mapping Intact Mass & Subunit
Data Analysis Bottleneck:Computational Pipelines to Automate Analysis
Generation 1: Peptide Mapping Analysis Pipeline
Data Acquisition
• Mass-SpecInstruments
• CRO
Identification
Thermo Proteome Discoverer• PMI Preview
(system & sample suitability)• SequestHT• PMI Byonic• Mascot Server
Peptide QuantitationSkyline (XICs)
Report
Excel, PPT
Vendor Specific Focused on PTMs – Separate Searches for Other Attributes
Manual Steps in Transferring Files Between Software Packages
Extensive time in data validation and report generation
Generation 2: End to End Pipeline for Accelerated Characterization
Mass-SpecInstruments
CRO
Peptide ID
Product Variants:• PTMs• Sequence Var• Glycation• Signal Peptide• Glycosylation• Clipping• Unknows
(Wildcard)
Biologics/ LabKey
End-to-End Automation
Byologic Viewer
Protein Metrics: BYOS
Intelligent False Positive Detection
Validation
1. Automated data sweep into search software – Vendor Agnostic2. Extensive Product Variant Search3. Reduce manual validation time – Define Criteria to flag false-positives4. Automated export of results5. Aggregate data with molecule information to build ‘In-house’ knowledge base (also auto QC)
Reporting: PDF / CSV
Exports
Data Acq. Data Aggregation
1
23
45
12
Automated Sweep Into Byos: Structured Data Folders & Filenames
BYOSData Files / Sequences Search Validate Report
Sequence Automatically Pulled from Master Database
13
BYOS Preset Workflow: Executes Multiple Enzyme Searches Depending on Files in the Project Folder
Identify enzymes based on folder name
Modifications ‘one-pot’ search:PTMs, Seq Var, Glycosylation,
Glycation, Signal Peptide, Wildcard, etc…
Report Template
14
Validation Through the Interactive GUI
15
Case 1: Developability
uSP Screen Developability Cell Line Selection
Sequence Variance
, Signal Peptide
PTM Analysis Generally Focuses on CDRs Where Modifications are Most Likely to Influence Potency
Heavy Chain Light ChainNIST Reference mAb
17
Automated Report Template
18
PTM Modification Tab
Chem Ox High pH Low PH Metal Ox Release Thermal
• Filter on specific modifications or molecule regions of interest
19
PTM Modification Tab
Chem Ox High pH Low PH Metal Ox Release Thermal
• Filter on specific modifications or molecule regions of interest
[Peak Eval] : Flag Identifications That Require Further Screening
All Results Exported to CSV to Allow for Additional Formatting and Reporting
20
Subunit PTM Region Motif %PTM Release
%PTM Chem Ox
%PTM Metal Ox
%PTM Low pH
%PTM High pH
%PTM Thermal
Heavy Chain
Oxidation CDR 1 W N.D. N.D. N.D. N.D. N.D. N.D.Oxidation CDR 2 W N.D. N.D. N.D. N.D. N.D. N.D.Oxidation CDR 3 W N.D. N.D. N.D. N.D. N.D. N.D.
Isomerization CDR 1 DS 0.61 0.38 0.59 0.32 20.30 5.96Deamidation CDR 1 NN 2.71* 3.29* 3.45* 2.13* 4.28* 3.18*
Light ChainOxidation CDR 1 W N.D. N.D. N.D. N.D. N.D. N.D.
Deamidation CDR 1 NL N.D. N.D. N.D. N.D. N.D. N.D.
Heavy Chain : FCOxidation CH3 M 6.14 31.81 7.28 6.59 7.70 13.84
Deamidation CH3 NN 4.37 4.20 4.63 3.96 28.28 12.73
* total of all deamidation states N.D. : Not Detected
Compare chemical stability profile across several candidates Correlate PTMs with bio-assay results on forced degradation samples
Feature Finder for Asp isomerization
21
Poster:P-249-M: Unexpected Asp-Isomerization Behavior in Therapeutic Proteins: Connecting Primary Structure with Higher Order Structure and Dynamics
22
Case 2: Cell Line Selection
uSP Screen Developability Cell Line Selection
Sequence Variance
, Signal Peptide
SVA in Clone Selection
SVA in Clone Selection
WT detectedRetention time shift
K/R varianceMonoisotopic Peak
Peptide Score Explained by common Mod
SVA Decision Treesequence variant annotated based on filter logic
25
Validated List of Sequence Variants for Eight Screened Clones
Protein Name Var. Pos. Mod. AA Mod. Names Sequence C3267B C3268B C3268C C3268D C3269B C3270B C3271B C3272B
CDS000045130 61 D Asp->Ala/-43.9898 R.LLIYSTSNLASGIPaR.F 0.00 0.00 0.00 0.00 0.32 0.00 0.00 0.00CDS000045130 105 L Leu->Val/-14.0157 K.vEIK.R 0.00 0.00 0.00 0.00 0.00 0.15 0.00 0.00CDS000045130 105 L Leu->Val/-14.0157 K.vEIKR.T 0 0 0 0 0 0.46 0 0CDS000055476 9 S Ser->Gly/-30.0106 -.qVQLVQSGgELK.K 0.00 0.00 1.43 0.00 0.00 0.00 0.00 0.00CDS000055476 34 M Met->Thr/-29.9928 K.ASGYTFTDYStHWVR.Q 0.00 0.00 0.00 0.05 0.11 0.12 0.00 0.00CDS000055476 256 M Met->Thr/-29.9928 K.DTLtISR.T 0.06 0.06 0.07 0.07 0.19 0.18 0.06 0.07CDS000055476 418 K Lys->Arg/28.0062 K.LTVDr.S 0.00 0.00 0.00 0.00 0.10 0.09 0.08 0.00
CLONE1 CLONE2 CLONE3 CLONE4 CLONE5 CLONE6 CLONE7 CLONE8
26
Case 3 : Signal Peptide Screening
uSP Screen Developability Cell Line Selection
Sequence Variance
, Signal Peptide
Transient ExpiCHO Expression for Unprocessed Signal Pepetide (uSP) Prediction
ExpiCHO transient expression platform
High expressing CHO-S cell line, optimized culture feed and efficient transfection reagent
7-day culture
Generate constructs with multiple leader sequence
Comparison of SP Levels in Bioreactor and Transient CHO Expression
MoleculeCHO Stable ExpiCHO**
Size of bioreactor %Total uSP %Total uSP
Molec 1 1000L 10.3 16.8
Molec 2 10L 1.6 1.0
Molec 3 2000L ND ND
Molec 4 250L 2.4 2.3
Molec 5
10L 6.0
4.650L 4.6
50L 5.4
Transient ExpiCHO Expression for Unprocessed Signal Pepetide (uSP) Prediction
ExpiCHO transient expression platform
High expressing CHO-S cell line, optimized culture feed and efficient transfection reagent
7-day culture
Generate constructs with multiple leader sequence
Molec Chain Signal Peptide Sequence uSP Motif uSP %
1HC MAWVWTLLFLMAAAQSIQA -- --
LC MARSALLILALLLLGLFSPGAWG -- --
2
HC MAWVWTLLFLMAAAQSIQA -- --
LC MAWSPLLLTLLAHCTGSWA
AWSPLLLTLLAHCTGSWA 3.8
LAHCTGSWA 0.8AHCTGSWA 0.6
HCTGSWA 0.4
3HC MAWVWTLLFLMAAAQSIQA -- --LC MAWALLLLTLLTRDTGSWA LLTRDTGSWA 5.3
Pipeline searches for all possible ragged clips to the leader sequence
Bottom Up and Intact Mass Approach for Molecule Characterization
29
Intact Mass & SubunitPeptide Mapping
Native Degly IdeSReduced
UNIFI WorkgroupIntact Mass Analysis Pipeline
Reduced, Alkylated
Trypsin Chymotrypsin
In-house Data Analysis Pipeline
Forced Deg Set, Clones, etc.
UNIFI Workgroup – Intact Mass Workflow
• Separates instrument control and data analysis
• Multiple scientists can work in parallel
• Streamline intact mass workflow:
Acquisition -> Processing -> Reporting -> ELN
• Scientific Library of Molecules – automated peak identification
• Reporting templates for different assays:• intact mass, reduced mass and sub-
units analysis
31
Unifi Automated Analysis – Early Clone Screening During CLD
Sampleg/L by RP
g/L by Octet
Rel. % Intact
Rel. % -AP Clip
Rel. % -A Clip
(14429.4 Da)
(14261.2 Da)
(14358.3 Da)
4319.DRP.1D2 3 2.8 91.8 6.5 1.84319-JZ2-23 2.2 1.7 85.3 10.8 44319.FA.4.D7 2.1 2.8 91.6 5.5 2.94319.RCN.1 2.1 2.5 86.4 8 5.64319-JZ1-5 2.1 1.4 94.4 4.2 1.44319.LG.F11 1.9 1.6 94.4 3.5 2.14319.VRH.4A9 1.9 1.5 91.1 5 3.94319.LG.C8* 1.8 2.2 -4319.RCN.4 1.8 1.7 90.7 5 4.34319-JZ2-12 1.8 1.9 88.9 5.9 5.14319.DRP.4F7 1.7 1.4 94.4 1.1 44319-JZ2-4 1.7 1.4 91.6 5 3.44319.RCN.6 1.6 1.4 87.6 10.5 1.94319.FA.1.C6 1.5 1.1 86.6 9.7 3.74319.RCN.3 1.5 1.6 87.6 10.5 1.94319-JZ2-1 1.5 1 88.9 5.9 5.14319-JZ2-29 1.5 1.4 93.1 4.8 2.14319.DRP.3B3 1.4 1 88.8 5.7 5.54319.FA.1.F4 1.3 0.9 86.7 8.8 4.6
4319.XS.MC2-0.5m-4 1.3 1.3 80.2 3.4 16.4
4319-JZ2-24 1.3 1.4 75.3 3.4 21.34319.FA.1.B6 1.2 1 82.4 3.3 14.34319.FA.1.F6 1.2 0.9 76.2 4.4 19.54319.LG.D12 1.2 1.2 92.8 4.5 2.74319.MS.2B8 1.2 1.1 93.6 4.8 1.64319.MS.2G10 1.2 1.1 95.6 4 2.14319.MS.2G7 1.2 1 93.9 4 2.14319.RCN.11 1.2 1.2 89 5.9 5.14319.XS.MC1-1m-2 1.2 1.6 88 2.2 9.84319.VRH.4D4 1.1 0.8 95 3.9 1.1
-AP
-A
Glycoprotein: Monitoring Potential Clipping Sites in Parental Clones
.
.
.
Data Acq.
Integrating Both Workflows Into One Data Analysis Pipeline
Mass-SpecInstruments
CRO
Peptide ID
Peptide Mapping Based Product Variant Search
Protein Metrics: BYOS – Master Script for End-to-End Automation
BYOSValidation
Joint Reporting
Comparison of
Modifications
Intact Mass Database
Intact Mass Deconvolution and Peak Annotation
Whole Protein or Subunit
Peptide Mapping
33
Conclusions Established workflow for in depth
characterization of molecules in early phase programs
Automation of data processing has allowed us to meet the challenges of fast turn-around-times and off-platform molecules Intelligent Filtering to Reduce Manual Validation Time (It will get
smarter as we do)Future Direction: Next generation pipeline to integrate intact/subunit and peptide map
characterizationModification knowledge base and data mgmt Automated clip and fragment detection by N-terminal Labeling (P-224-M)
Acknowledgements
Bo ZhaiAndy MahanHarsha GunawardenaEric BeilJeff BrelsfordBarry Morse
Eric CarlsonJing LiYong Joo KilAndrew NicholsIlker Sen